Sandwich-type lateral flow assay devices, systems, and methods described herein measure concentration of an analyte of interest in a sample, and can determine the precise concentration of the analyte when it is present at high concentrations. A signal of maximum intensity is generated when the concentration of analyte of interest in a sample is zero. For low concentrations of analyte, the lateral flow assays described herein generate signals that are the same as or substantially equivalent to the maximum intensity signal. High concentrations of the analyte of interest generate signals that are less than the maximum intensity signal. Lateral flow assays of the present disclosure solve drawbacks associated with the hook effect of sandwich-type lateral flow assays by eliminating the phase of the dose response curve where signals are increasing.

Reagents for use in sandwich immunoassays for haptens are disclosed, along with kits containing same. Also disclosed are diagnostic immunoassay methods that utilize these immunoassay reagents in a particle enhanced agglutination detection assay for detecting haptens/drugs in samples.

Disclosed is a method for measuring an Aβ peptide in a blood sample in vitro, comprising: measuring the Aβ peptide by an immunoassay using an antibody set comprising a capture antibody and a detection antibody that specifically bind to the Aβ peptide, wherein the capture antibody is an antibody that binds to an epitope comprising an N-terminal residue of the Aβ peptide, the detection antibody is an antibody that binds to an epitope different from the epitope to which the capture antibody binds, and the Aβ peptide is at least one selected from the group consisting of Aβ40 or Aβ42.

A method and a diagnostic agent kit for detecting viral liver cancer having excellent sensitivity and specificity are provided.

The problem can be solved by a method for detecting viral liver cancer, comprising measuring an amount of free AIM in a biological sample from a subject and comparing the measured amount of free AIM with a reference value.

Alternative antibodies to screen for SARS-CoV-2 are disclosed. One alternative antibody is Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1056 (“E3-Antibody” or “E3”), from EastCoast Bio, Inc., PO Box 489, North Berwick, Me. 03906, USA (“EastCoast Bio”). Another alternative antibody is a combination of the E3-Antibody and Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1057 (“E1-Antibody” or “E1”), from EastCoast Bio (the combination of the E1-Antibody and the E3-Antibody is designated as “E1/E3-Antibody” or simply “E1/E3”). Yet another alternative antibody is a combination of Mouse Species Anti-SARS-CoV-2 NP mAb, clone 4B21, Catalog Number CABT-CS027 (“C4-Antibody” or “C4”), from Creative Diagnostics, 45-1 Ramsey Road, Shirley, N.Y. 11967, USA (“Creative Diagnostics”), and Mouse Species Anti-SARS-CoV-2 NP mAb, clone 7G21, Catalog Number CABT-CS026 (“C5-Antibody” or “C5”), also from Creative Diagnostics (the combination of the C4-Antibody and the C5-Antibody is designated as “C4/C5-Antibody” or simply “C4/C5”).

The present disclosure relates generally to peptide reporter constructs of SNAP-25, which are useful in determining the activity of botulinum toxins, and methods of using the same.

The present invention provides a lateral flow test device for detecting a coronavirus antibody by immunoassay; the test device includes three lateral flow test strips; a first test strip is directed to the antibody detection of a N full-length protein and/or an S full-length protein antigens/antigen; and a second test strip is directed to the antibody detection of an S-RBD-site protein antigen, and both of the first strip and the second strip are combined to detect novel coronavirus IgG and IgM antibodies, which can practically reduce the possibility of missing detection and wrong detection; further, a third test strip is directed to the detection of a neutralizing antibody at an S-RBD site to rapidly detect the neutralizing antibody having protection effect, thus further helping the prevention of missing detection and helping patients to perform self-detection and judge the situations of recovery, or vaccine immunity.

The present invention relates to a quantum dot-containing nanoparticle comprising: a core part; a quantum dot part bound to a surface of the core part; a shell part for protecting the core part and the quantum dot part; and a support part for supporting the binding of the core part and the shell part, wherein the nanoparticle exhibits a high occupied area and stable binding, thereby exhibiting improved luminous efficiency (QY) and brightness when detecting a biological sample (biomolecule).

The invention provides an immunological binding partner specifically reactive with a C-terminal epitope of the α1 chain of collagen Type VIII or with an N-terminal epitope of the mature form of the α1 chain of collagen Type VIII, and a method of immunoassay for detecting or quantitating in a sample the C-terminal epitope or the N-terminal epitope of the mature α1 chain of collagen type VIII.

The composition includes a first construct having a first portion of a protein and a first antigen-recognizing amino acid sequence; and a second construct having a second portion of the protein that catalyzes a reaction when combined with the first portion of the protein and a second antigen-recognizing amino acid sequence. The first and second synthetic constructs include a sulfhydryl group configured such that a disulfide bond is formed between the first and second synthetic constructs when the first antigen-recognizing amino acid sequence and the second antigen-recognizing amino acid sequence bind an antigen.